Equities analysts predict that KemPharm, Inc. (NASDAQ:KMPH) will post ($0.63) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for KemPharm’s earnings. KemPharm posted earnings per share of ($0.58) in the same quarter last year, which suggests a negative year over year growth rate of 8.6%. The company is scheduled to issue its next quarterly earnings report on Wednesday, August 9th.

On average, analysts expect that KemPharm will report full-year earnings of ($2.75) per share for the current fiscal year, with EPS estimates ranging from ($2.81) to ($2.70). For the next year, analysts expect that the company will post earnings of ($2.23) per share, with EPS estimates ranging from ($2.50) to ($1.95). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover KemPharm.

KemPharm (NASDAQ:KMPH) last announced its quarterly earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by $0.21.

KMPH has been the subject of several research reports. Zacks Investment Research upgraded KemPharm from a “hold” rating to a “buy” rating and set a $4.75 target price for the company in a report on Tuesday, March 14th. Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of KemPharm in a report on Wednesday, March 22nd. Royal Bank Of Canada set a $8.00 target price on KemPharm and gave the stock a “buy” rating in a report on Wednesday, April 12th. Roth Capital initiated coverage on KemPharm in a report on Wednesday, June 28th. They issued a “buy” rating and a $8.00 target price for the company. Finally, ValuEngine upgraded KemPharm from a “strong sell” rating to a “sell” rating in a report on Saturday, July 1st. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. KemPharm currently has a consensus rating of “Hold” and an average target price of $8.10.

In related news, CEO Travis C. Mickle acquired 8,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 20th. The stock was purchased at an average cost of $3.45 per share, for a total transaction of $27,600.00. Following the purchase, the chief executive officer now directly owns 1,629,612 shares of the company’s stock, valued at approximately $5,622,161.40. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have purchased a total of 10,775 shares of company stock valued at $38,783 over the last 90 days. 22.80% of the stock is currently owned by company insiders.

Large investors have recently modified their holdings of the company. Bank of New York Mellon Corp boosted its stake in shares of KemPharm by 17.6% in the first quarter. Bank of New York Mellon Corp now owns 22,854 shares of the specialty pharmaceutical company’s stock worth $112,000 after buying an additional 3,414 shares during the period. Victory Capital Management Inc. bought a new stake in shares of KemPharm during the first quarter worth $647,000. C WorldWide Group Holding A S boosted its stake in shares of KemPharm by 10.1% in the first quarter. C WorldWide Group Holding A S now owns 181,699 shares of the specialty pharmaceutical company’s stock worth $890,000 after buying an additional 16,699 shares during the period. Finally, Creative Planning boosted its stake in shares of KemPharm by 2.3% in the first quarter. Creative Planning now owns 453,723 shares of the specialty pharmaceutical company’s stock worth $2,223,000 after buying an additional 10,200 shares during the period. Hedge funds and other institutional investors own 42.11% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Zacks: Brokerages Expect KemPharm, Inc. (KMPH) Will Announce Earnings of -$0.63 Per Share” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/07/11/zacks-brokerages-expect-kempharm-inc-kmph-will-announce-earnings-of-0-63-per-share.html.

Shares of KemPharm (NASDAQ KMPH) traded up 2.67% during mid-day trading on Tuesday, reaching $3.85. The company had a trading volume of 50,555 shares. The firm has a 50-day moving average price of $3.91 and a 200-day moving average price of $3.89. KemPharm has a 1-year low of $2.90 and a 1-year high of $5.50. The stock’s market capitalization is $56.39 million.

KemPharm Company Profile

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Get a free copy of the Zacks research report on KemPharm (KMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.